Divij Mathew

机构：California University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Translational Therapeutics (United States), Institute of Immunology, Immune Regulation (United Kingdom), University of Pennsylvania · ORCID：0000-0002-8323-7358

发表论文 103 篇 · 总被引 9946 次 · h-index 36

代表论文

• Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients (2024 · Science · 被引 231)
• Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells (2024 · Cancer Cell · 被引 112)
• LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity (2024 · Cell · 被引 108)
• Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and roles in disease (2025 · Nature Immunology · 被引 19)
• Recovery of biological signals lost in single-cell batch integration with CellANOVA (2024 · Nature Biotechnology · 被引 18)
• Automated cytometric gating with human-level performance using bivariate segmentation (2025 · Nature Communications · 被引 10)